Navigation Links
Research Report on China's Anti-Prostatic Hyperplasia (PH) Drug Market, 2013-2017
Date:6/12/2013

DUBLIN, June 12, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/3c9pm9/research_report) has announced the addition of the "Research Report on China's Anti-Prostatic Hyperplasia (PH) Drug Market, 2013-2017" report to their offering.
     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

Benign prostatic hyperplasia (BPH) is a common disease among middle-aged and elderly men, with an increasing morbidity as the rise in ages. Its invasion is possibly related to race and regions.

In China, the PH morbidity of men in urban regions is far higher than that in rural regions. The PH morbidity is influenced by several factors: the morbidity of married people higher than that of unmarried ones and the relatively high morbidity among patients suffering from diseases in the nervous system, respiratory system and reproductive system. The morbidity of people with a family history of PH is over 50%.

Only under severe symptoms will PH patients need the surgical treatment. In most cases, the long-term drug treatment is adopted. Currently, the common clinical drugs include receptor blocking agents, antiandrogen drugs, traditional Chinese medicine preparations, plant preparations, etc.

In 2012, the market size of China's hospital-use anti-PH drugs reached CNY 3.67 billion, increasing by 12.6% YOY.

Four drug varieties, namely, Finasteride, Tamsulosin, Doxazosin and Cernilton dominate China's hospital-use anti-PH drug market. In 2011, it controlled nearly 80% of hospital-use anti-PH drug market nationwide.

In the coming years, a large group of branded drugs will successively lose patent protection, which is a great opportunity for non-patent drug manufacturers. Meanwhile, it is also a huge market. Therefore, the prospect of China's anti-PH drug market is very bright. The annual growth rate of China's anti-PH drug market size is predicted to be over 10% in years to come.

More following information can be acquired through this report:

- Current R&D Status of Anti-PH Drugs
- Competition in China's Anti-PH Drug Market
- Market Sizes of China's Major Anti-PH Drugs
- Prediction on Development of China's Anti-PH Drugs

Following people are recommended to buy this report:

- Anti-PH Drug Manufacturers
- Pharmaceutical Agents/Hospitals
- Investors and Research Institutions Focusing on Anti-PH Drugs

Key Topics Covered:

1 Overview on Anti-Prostatic Hyperplasia (PH) Drugs
1.1 Definition of Prostatic Hyperplasia
1.2 Incidence

2 Overview on China's Anti-PH Drug Market, 2011-2012
2.1 Market Size
2.2 Market Shares of Major Drugs
2.3 Market Shares of Manufacturers

3 Analysis on Major Anti-PH Drugs in China's Market
3.1 5a-reductase Inhibitors
3.1.1 Finasteride
3.1.2 Epristeride
3.1.3 Dutasteride
3.2 a 1-adrenaline Receptor Antagonists
3.2.1 Tamsulosin
3.2.2 Doxazosin
3.2.3 Terazosin
3.2.4 Alfuzosin
3.3 Phytomedicine-Cernilton

4 Survey of Major Anti-PH Drug Prices in China's Market, 2011-2013

5 Prediction on Development of China's Anti-PH Drugs, 2013-2017
5.1 Prediction on Market Size
5.2 Prediction on Technological Trends

For more information visit http://www.researchandmarkets.com/research/3c9pm9/research_report
Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals


'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Wolters Kluwer Research Now Available via Bloomberg Tradebook
2. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
3. New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers
4. Researching graphene nanoelectronics for a post-silicon world
5. In new quantum-dot LED design, researchers turn troublesome molecules to their advantage
6. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
7. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
8. Multidisciplinary team of researchers develop world’s lightest material
9. K computer research results awarded ACM Gordon Bell Prize
10. ResearchMoz: Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market
11. Researchers shrink tumors and minimize side effects using tumor-homing peptide to deliver treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and ... clinical trial team. , Using the CONSULT module, patients and physicians can schedule a ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
Breaking Biology Technology:
(Date:6/1/2016)... Favorable Government Initiatives Coupled With ... Identification to Boost Global Biometrics System Market Through 2021  ... report, " Global Biometrics Market By Type, By ... 2011 - 2021", the global biometrics market is projected ... of growing security concerns across various end use sectors ...
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
Breaking Biology News(10 mins):